US biopharma firm Marina Biotech (OTCQB: MRNA) has entered into a license agreement regarding its SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics.
This represents the first time that the company's SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics. Under terms of the agreement, Marina could receive up to $90 million in success based milestones.
Further details of the agreement, including the name of the company licensing the technology, were not disclosed. However, news of the deal sent Marina’s share soaring 47.3% to $0.20 by mid-morning trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze